Labcorp and Waters Corporation announced a strategic partnership to integrate the BD Onclarity HPV Assay into Labcorp's network starting late 2026. This collaboration aims to expand access to cervical cancer screening and HPV genotyping, leveraging Labcorp's infrastructure for broader patient reach.
Labcorp and Waters Corporation have formed a strategic partnership to integrate the BD Onclarity HPV Assay into Labcorp's national laboratory network, with rollout slated for late 2026. This initiative is significant as it aims to expand access to cervical cancer screening and HPV genotyping, aligning with ASCCP guidelines. Labcorp benefits by enhancing its diagnostic service portfolio and leveraging its extensive infrastructure for broader patient access, potentially increasing testing volumes in the long term. Waters Corporation gains from its technology being integrated into a major diagnostic network, expanding its market reach. While the rollout is not immediate, this collaboration represents a strategic move for both companies in the diagnostics space. For traders, this is a moderate positive for LH and WAT, signaling future revenue opportunities, though the delayed implementation means no immediate material impact.